Broad Institute Limited License
Abcam provides its modified cell lines that have been generated using CRISPR Cas9 technology under a license agreement with the Broad Institute, Inc. ("Broad") that contains certain limitations and obligations. By purchasing such modified cell lines, you, (the “Buyer”), hereby agree to use the modified cell lines for your own internal research only, and in accordance with the Limited License below:
The following definitions apply to the Limited License:
Commercial Purposes means (a) the practice, performance or provision of any method, process or service, or (b) the manufacture, production, sale, use, distribution, disposition or importing of any product, in each case (a) or (b) for consideration of any kind, for the purpose of sale or commercial exploitation, or on any other commercial basis.
Company means Abcam Ltd
-.
Enabled Product means any product, that is not the Licensed Product, which is or incorporates (a) any progeny, modification or derivative of the Licensed Product, or (b) any cell, organism or animal made or modified through use of the Licensed Product, or any progeny, modification or derivative of such cell, organism or animal. For clarity, any product that is made, produced or derived by use of the technology of the Patent Rights, such as a protein or a peptide from a cell line shall be deemed an Enabled Product; provided, however, that the term Enabled Product shall not include any large or small molecule that(i) was identified or discovered through screening using technology covered by the Patent Rights and (ii) does not otherwise fall within the foregoing clauses (a) through (b).
Field means use as a research tool for research purposes; provided, however, that notwithstanding the foregoing, the Field shall expressly exclude (a) any clinical use, including, without limitation, diagnostic and prognostic use,(b) any human, veterinary, livestock or agricultural use, or (c) the manufacture, distribution, importation, exportation, transportation, sale, offer for sale, marketing, promotion or other exploitation or use of, or as, a testing service, therapeutic or diagnostic for humans or animals.
Indemnitees means each Licensor Party, their affiliates, and their current and former trustees, directors, officers, faculty, affiliated investigators, students, employees, medical and professional staff and agents and their respective successors, heirs and assigns
Licensed Patent Rights means (a) any patents and patent applications listed in the Broad Institute Patent Rights table below; (b) any substitutions, divisions, continuations, reissues, renewals, re-examinations or extensions of any patents or patent applications of (a), any continuations-in-part of any patents or patent applications of (a) to the extent the claims are directed to subject matter specifically described in a patent or patent application set forth on Appendix A, and any application claiming priority to a provisional application listed in the Broad Institute Patent Rights table below, to the extent the claims are directed to subject matter specifically described in a provisional patent application set forth on Appendix A; (c) any letters patents and/or the equivalent issuing therefrom in any jurisdiction based on any of the foregoing; and (d) any foreign or international equivalents of any of the foregoing, including without limitation any applications filed under the Patent Cooperation Treaty.
Licensor Parties means the Broad Institute, Inc.; the President and Fellows of Harvard College, Massachusetts Institute of Technology, University of Iowa Research Foundation; University of Tokyo; Rockefeller University; New York University, New York Genome Center.
Product means any product (a) that is Covered by at least one Claim of the Patent Rights or (b) that is not described in the foregoing clause (a) but that includes, uses, is derived from or is developed, identified or made through the use of technology Covered by at least one Claim of the Patent Rights or a product covered by the foregoing clause (a) (including any biological material, cell, organism or animal so derived, developed, identified or made) and any progeny, modifications, improvements or derivatives thereof; provided, however, that the term “Product” shall not include (A) any therapeutic large or small molecule that (i) was identified through screening using the technology Covered by the Patent Rights and (ii) does not otherwise make use of the Patent Rights or (B) any product that would not otherwise be a Product except for the use of a Product, Process or the technology Covered by at least one Claim of the Patent Rights solely for purposes of Company’s internal quality control or validation.
Broad Institute Patent Rights
EXEMPLARY FAMILY SERIAL NO | PATENT TITLE |
PCT/US2013/074611 | CRISPR-CAS Component Systems, thods and Compositions for Sequence Manipulation |
PCT/US2013/074743 | CRISPR-CAS Systems and Methods for Altering Expressions of Gene Products |
14/259,420 | CRISPR-CAS Systems, Methods and Compositions For Sequence Manipulation in Eukaryotes |
PCT/US2013/051418 | Inducible DNA Binding Proteins and Genome Perturbation Tools and Applications Thereof |
PCT/US2013/074825 | Methods, Systems and Apparatus for Identifying Target Seuqences for CAS Enzymes or CRISPR-CAS Systems for Target Sequences and Conveying Results Thereof |
PCT/US2013/074812 | Methods, Models, Systems and Apparatus for Identifying Target Sequences for CAS Enzymes or CRISPR-CAS Systems for Target Sequences and Conveying Results Thereof |
PCT/US2013/074667 | Delivery, Engineering and Optimization of Systems Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
PCT/US2014/041803 | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Applications |
PCT/US2013/074691 | Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation |
PCT/US2013/074736 | Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation with Functional Domains |
PCT/US2013/074819 | Engineering of Systems, Methods and Optimized Guide Compositions for Sequence Manipulation |
14/855,046 | Recombinant Virus And Preparations Thereof |
PCT/US2014/041800 | Delivery, Engineering and Optimization of Tandem Guide Systems, Methods and Compositions for Sequence Manipulation |
PCT/US2014/041806 | Fiunctional Genomics Using CRISPR-Cas Systems, Compositions, Methods, Screens and Applications Thereof |
PCT/US2014/064663 | CRISPR-Related Methods and Compositions with Governing gRNAS |
PCT/US2014/069902 | Compositions and Methods of Use of CRISPR-Cas Systems in Nucleotide Repeat Disorders |
PCT/US2014/069897 | Compositions and Methosd of Use of CRISPR-CAS Systems in Nucleotide Repeat Disorders |
15/171,141 | CRISPR-CAS Systems, Crystal Structure and Uses Thereof |
15/349,603 | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
15/467,949 | Use and Production of CHD8+/- Transgenic Animals with Behavioral Phenotypes Characteristic of Autism Spectrum Disorder |
15/469,081 | Functional Screening with Optimized Functional CRISPR-Cas Systems |
PCT/US2015/067177 | CRISPR Having or Associated with Destabilization Domains |
PCT/US2015/065385 | Protected Guide RNAs (PGRNAs) |
15/632,067 | RNA-Targeting System |
PCT/US2015/067138 | Unbiased Identification of Double- Strand Breaks and Genomic Rearrangement by Genome-Wide Insert Capture Sequencing |
PCT/US2015/065393 | Dead Guides for CRISPR Transcription Factors |
15/619,735 | Escorted and Functionalized Guides for CRISPR-CAS Systems |
15/619,737 | Delivery, Use and Therapeutic Applications of CRISPR Systems and Compositions for Genome Editing as to Hematopoietic Stem Cells (HSCs) |
15/640,103 | CRISPR MEDIATED IN VIVO MODELING AND GENETIC SCREENING OF TUMOR GROWTH AND METASTASIS |
PCT/US2016/038252 | Engineering and Optimization of Systems, Methods, Enzymes and Guide Scaffolds of CAS9 Orthologs and Variants for Sequence Manipulation |
PCT/US2016/038034 | CRISPR Enzyme Mutations Reducing Off-Target Effects |
PCT/US2016/038205 | CRISPR Mediated Recording of Cellular Events |
PCT/US2017/047458 | Novel CRISPR Enzymes and Systems |
PCT/US2017/053795 | Systematic Screening and Mapping of Regulatory Elements in Non-Coding Genomic Regions, Methods, Compositions, and Applications Thereof |
62/502,064 62/564,102 | Methods for Identification and Modification of LNCRNA Associated with Target Genotypes and Phenotypes |
62/529,573 | Methods for Designing Guides Sequences for Guided Nucleases |
PCT/US2014/070068 | CRISPR-CAS Systems and Methods for Altering Expression of Gene Products, Structural Information and Inducible Modular CAS Enzymes |
PCT/US2014/041804 | DELIVERY AND USE OF THE CRISPR- CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY |
PCT/US2014/070127 | Delivery, Use and Therapeutic Applications of the CRISPR-Cas Systems and Compositions for Genomic Editing |
PCT/US2014/041808 | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Targeting and Modeling Diseases and Disorders of Post Mitotic Cells |
PCT/US2014/041809 | Delivery, Use and therapeutic Applications of the CRISPR-Cas systems and Compositions for Targeting Disorders and Diseases Using Viral Components |
PCT/US2014/070057 | Delivery, Use and Therapeutic Applications of the CRISPR-CAS Systems and Compositions for Targeting Disorders and Diseases Using NanoParticle Components |
PCT/US2013/074800 | Functional Genomics Using CRISPR- CAS Systems, Compositions, Methods, Knock Out Libraries and Applications Thereof |
PCT/US2014/070152 | Engineering Of Systems, Methods And Optimized Guide Compositions with New Architectures For Sequence Manipulation |
PCT/US2014/070175 | Systems, Methods and Compositions for Sequence Manipulation with Optimized Functional CRISPR-CAS Systems |
PCT/US2015/045504 | Genome Editing Using CAS9 Nickases |
15/467,888 | Delivery, Use and Therapeutic Applications of the CRISPR-CAS Systems and Compositions for Modeling Competition of Multiple Cancer Mutations in Vivo |
ERS Genomics Terms of Use
Abcam provides its modified cell lines that have been generated using CRISPR Cas9 technology under a license agreement with the ERS Genomics Limited ("ERS") that contains certain limitations and obligations. By purchasing such modified cell lines, you, the buyer, hereby agree to use the modified cell lines for your own internal research only, and in accordance with the Terms of Use set out below:
BEFORE PLACING AN ORDER OR USING THIS PRODUCT, PLEASE READ THE TERMS AND CONDITIONS SET FORTH BELOW. YOUR PURCHASE OF THIS PRODUCT SHALL CONSTITUTE ACKNOWLEDGMENT AND ACCEPTANCE OF THESE TERMS AND CONDITIONS.
Certain commercial entities and/or activities performed at commercial entities may require additional contract rights from ERS Genomics Limited which are not granted through the purchase of this product. For additional information please see www.ersgenomics.com/research-products.php.
The buyer receives a non-exclusive, non-transferable right to use the Product, Progeny (meaning any unmodified descendant form of the Product), Modifications (meaning any modifications of the Product) and Unmodified Derivatives (meaning any substances created by the buyer which constitute an unmodified functional subunit or product expressed by the Product) for RESEARCH USE ONLY, which, subject to the exclusions below, includes use to discover and develop any product, including therapeutic products, which may then be sold to third parties, provided, however, that such products do not incorporate the Product, Progeny, Modifications, or Unmodified Derivatives.
No “Commercial Use” is allowed. Commercial Use means any and all uses of the Product, Progeny, Modifications or Unmodified Derivatives thereof, or any modified cells or organisms created through use of the foregoing, including but not limited to:
(1) Sale, whether or not such sale is limited for use in research;
(2) Provision of a service to a third party;
(3) Use in any diagnostic, preventative, or therapeutic application;
(4) Use in any veterinary, livestock or agricultural application;
(5) Use in later stage development of therapeutics, diagnostics, prophylactics (e.g., hit-to-lead, lead optimization); and
(6) Manufacturing of a product for sale.
For clarity, transfer of materials or provision of services by not for profit or academic core labs to their internal clients shall not constitute a Commercial Use.
Except for the rights granted herein, any and all rights to the Product, Progeny, Modifications or Unmodified Derivatives thereof, shall remain in Abcam. No ownership rights are transferred.
The buyer shall have no right to assign the rights granted herein to third parties. The Product, Progeny, Modifications or Unmodified Derivatives thereof, must at all times remain in the possession of the buyer, except for a transfer to a scientific collaborator or to a service provider, to perform services, solely on behalf of the buyer.
ERS Genomics Limited is an intended third-party beneficiary under these Terms of Use.
ERS Genomics Limited Patent Rights (July 2019)
Granted Patents | ||||
Country | Application No. | Filing Date | Patent No. | Grant Date |
AU | 2013266968 | 15 Mar 2013 | AU 2013266968 B2 | 07 Dec 2017 |
CN | 201380038920.6 | 15 Mar 2013 | CN 104854241 B | 14 Jul 2017 |
EP | 13793997.1 | 15 Mar 2013 | EP 2800811 B1 | 10 May 2017 |
EP | 17163434.8 | 15 Mar 2013 | EP 3241902 B1 | 28 Feb 2018 |
EP | 18152360.6 | 15 Mar 2013 | EP 3401400 B1 | 03 Apr 2019 |
GB | 1420270.9 | 15 Mar 2013 | GB 2518764 C | 02 Mar 2016 |
GB | 1601071.2 | 15 Mar 2013 | GB 2537000 B | 08 Mar 2017 |
HK | 15106335.4 | 03 Jul 2015 | HK 1207107 B | 25 Aug 2017 |
HK | 15112610.8 | 23 Dec 2015 | HK 1211978 B | 04 May 2018 |
HK | 17103002.1 | 03 Jul 2015 | HK 1230233 B | 01 Jun 2018 |
JP | 20150514015 | 15 Mar 2013 | JP 6343605 B | 25 May 2018 |
MX | 20140014477 | 15 Mar 2013 | MX 349744 B | 10 Aug 2017 |
NZ | 714353 | 15 Mar 2013 | NZ 714353 B2 | 29 Aug 2017 |
SG | 11201407702 | 15 Mar 2013 | SG 11201407702X | 20 Mar 2017 |
SG | 10201701800Y | 15 Mar 2013 | SG 10201701800Y | 21 Nov 2018 |
TN | 2014/0493 | 25 Nov 2014 | TN 24223 | 03 Jun 2016 |
UA | A201413835 | 15 Mar 2013 | UA 118014 | 12 Nov 2018 |
US | 13/842,859 | 15 Mar 2013 | US 10266850 B2 | 23 Apr 2019 |
US | 14/685,502 | 13 Apr 2015 | US 10000772 B2 | 19 Jun 2018 |
US | 14/942,782 | 16 Nov 2015 | US 10227611 B2 | 12 Mar 2019 |
US | 15/138,604 | 26 Apr 2016 | US 10113167 B2 | 30 Oct 2018 |
ZA | 2014/07881 | 29 Oct 2014 | ZA 2014/07881 | 31 Jan 2018 |
DE | 2020132012240.4 | 15 Mar 2013 | DE 202013012240 U1 | 02 Feb 2016 |
DE | 2020132012241.2 | 15 Mar 2013 | DE 202013012241 U1 | 18 Jan 2016 |
DE | 2020132012242.0 | 15 Mar 2013 | DE 202013012242 U1 | 02 Feb 2016 |
Patent Applications | ||||
Country | Application No. | Filing Date | Publication No. | Publication Date |
PCT | PCT/US2013/032589 | 15 Mar 2013 | WO 2013/176772 A1 | 28 Nov 2013 |
AE | P1296/2014 | 25 Nov 2014 | ||
AU | 2017225060 | 07 Sep 2017 | AU 2017225060 A1 | 28 Sep 2017 |
AU | 2019201850 | 18 Mar 2019 | ||
BR | 1120140294410 | 15 Mar 2013 | BR 1120140294410 A2 | 27 Jun 2017 |
CA | 2872241 | 15 Mar 2013 | CA 2872241 A1 | 28 Nov 2013 |
CL | 2014003208 | 25 Nov 2014 | CL 2014003208 A1 | 19 Jun 2015 |
CN | 201710585690.5 | 15 Mar 2013 | CN 107603976 A | 19 Jan 2018 |
CO | 20140259531 | 25 Nov 2014 | CO 7151523 A2 | 29 Dec 2014 |
CR | 20140538 | 24 Nov 2014 | CR 20140538 A | 18 Feb 2015 |
DZ | 140780 | 22 Dec 2014 | ||
EA | 201401319 | 15 Mar 2013 | EA 201401319 A1 | 29 May 2015 |
EC | IEPI-2014-28704 | 15 Mar 2013 | 30 Oct 2015 | |
EG | PCT1887/2014 | 15 Mar 2013 | ||
EP | 19157590.1 | 15 Mar 2013 | ||
GB | 1511669.2 | 15 Mar 2013 | GB 201511669 D0 | 19 Aug 2015 |
GE | AP2013013674 | 15 Mar 2013 | ||
HK | 15104473.1 | 12 May 2015 | HK 1204003 A1 | 06 Nov 2015 |
HK | 19119875.3 | 22 Feb 2019 | ||
ID | P00201407783 | 10 Dec 2014 | 2016/03367 | 13 May 2016 |
IL | 235461 | 15 Mar 2013 | 31 Dec 2014 | |
IL | 261563 | 15 Mar 2013 | 31 Oct 2018 | |
IL | 261565 | 15 Mar 2013 | 31 Oct 2018 | |
IL | 261566 | 15 Mar 2013 | 31 Oct 2018 | |
IL | 261567 | 15 Mar 2013 | 31 Oct 2018 | |
IL | 261568 | 15 Mar 2013 | 31 Oct 2018 | |
IL | 261569 | 15 Mar 2013 | 31 Oct 2018 | |
IL | 261570 | 15 Mar 2013 | 31 Oct 2018 | |
IN | 2995/KOLNP/2014 | 15 Mar 2013 | 2995/KOLNP/2014 A | 04 Dec 2015 |
JP | 2018-097369 | 21 May 2018 | 2018-138054 | 06 Sep 2018 |
KE | P/2014/002178 | 25 Nov 2014 | ||
KR | 1020147036096 | 15 Mar 2013 | KR 1020150016588 A | 12 Feb 2015 |
KR | 1020177034069 | 15 Mar 2013 | KR 1020170134766 A | 06 Dec 2017 |
KS | P/2017/000022 | 15 Mar 2013 | ||
LY | 4958/2014 | 15 Mar 2013 | ||
MA | 37663 | 15 Mar 2013 | MA 37663 A1 | 31 May 2017 |
MX | 2017010309 | 15 Mar 2013 | ||
MX | 2019001995 | 15 Mar 2013 | ||
MY | PI2014003102 | 15 Mar 2013 | ||
MY | PI2018700285 | 15 Mar 2013 | ||
NZ | 701326 | 15 Mar 2013 | ||
NZ | 728024 | 15 Mar 2013 | NZ 728024 A | 27 Jan 2017 |
NZ | 730667 | 15 Mar 2013 | NZ 730667 A1 | 31 Mar 2017 |
OM | P/2014/00268 | 25 Nov 2014 | ||
PA | 90441-01 | 25 Nov 2014 | 12 Sep 2016 | |
PE | 002211-2014/DIN | 15 Mar 2013 | PE 03362015 A1 | 25 Mar 2015 |
PH | 12014502574 | 19 Nov 2014 | PH 12014502574 A1 | 21 Jan 2015 |
QA | 20141100400 | 15 Mar 2013 | ||
SG | 10201809817U | 15 Mar 2013 | SG 10201809817U A | 28 Dec 2018 |
SY | 2014120156 | 15 Mar 2013 | ||
TH | 1401007063 | 15 Mar 2013 | TH 173084 | 15 Feb 2018 |
UA | A201808549 | 07 Aug 2018 | ||
US | 61/652,086 | 25 May 2012 | ||
US | 61/716,256 | 19 Oct 2012 | ||
US | 61/757,640 | 28 Jan 2013 | ||
US | 61/765,576 | 15 Feb 2013 | ||
US | 14/403,475 | 24 Nov 2014 | US 2016/0046961 A1 | 18 Feb 2016 |
US | 14/685,504 | 13 Apr 2015 | US 2016/0130609 A1 | 12 May 2016 |
US | 14/685,513 | 13 Apr 2015 | US 2016/0060653 A1 | 03 Mar 2016 |
US | 14/685,514 | 13 Apr 2015 | US 2016/0060654 A1 | 03 Mar 2016 |
US | 14/685,516 | 13 Apr 2015 | US 2016/0068864 A1 | 10 Mar 2016 |
US | 15/090,511 | 04 Apr 2016 | US 2017/0051312 A1 | 23 Feb 2017 |
US | 15/343,156 | 03 Nov 2016 | ||
US | 15/343,158 | 03 Nov 2016 | ||
US | 15/435,233 | 16 Feb 2017 | US 2017/0166893 A1 | 15 Jun 2017 |
US | 15/803,424 | 03 Nov 2017 | US 2018/0282764 A1 | 04 Oct 2018 |
US | 15/915,020 | 07 Mar 2018 | US 2019/0062790 A1 | 28 Feb 2019 |
US | 15/925,544 | 19 Mar 2018 | US 2018/0208931 A1 | 26 Jul 2018 |
US | 15/947,680 | 06 Apr 2018 | US 2018/0230495 A1 | 16 Aug 2018 |
US | 15/947,700 | 06 Apr 2018 | US 2018/0230496 A1 | 16 Aug 2018 |
US | 15/947,718 | 06 Apr 2018 | US 2018/0230497 A1 | 16 Aug 2018 |
US | 15/959,715 | 23 Apr 2018 | US 2018/0298406 A1 | 18 Oct 2018 |
US | 15/959,735 | 23 Apr 2018 | US 2018/0298407 A1 | 18 Oct 2018 |
US | 15/959,762 | 23 Apr 2018 | US 2018/0237801 A1 | 23 Aug 2018 |
US | 15/959,782 | 23 Apr 2018 | US 2018/0245100 A1 | 30 Aug 2018 |
US | 15/959,802 | 23 Apr 2018 | US 2018/0273981 A1 | 27 Sep 2018 |
US | 15/965,598 | 27 Apr 2018 | US 2018/0245101 A1 | 30 Aug 2018 |
US | 15/965,603 | 27 Apr 2018 | US 2018/0251791 A1 | 06 Sep 2018 |
US | 15/981,807 | 16 May 2018 | US 2018/0251793 A1 | 06 Sep 2018 |
US | 15/981,808 | 16 May 2018 | US 2018/0251794 A1 | 06 Sep 2018 |
US | 15/981,809 | 16 May 2018 | US 2018/0251795 A1 | 06 Sep 2018 |
US | 16/033,002 | 11 Jul 2018 | US 2018/0312874 A1 | 01 Nov 2018 |
US | 16/033,005 | 11 Jul 2018 | US 2018/0312875 A1 | 01 Nov 2018 |
US | 16/033,016 | 11 Jul 2018 | US 2018/0312876 A1 | 01 Nov 2018 |
US | 16/136,159 | 19 Sep 2018 | US 2019/0002921 A1 | 03 Jan 2019 |
US | 16/136,165 | 19 Sep 2018 | US 2019/0002922 A1 | 03 Jan 2019 |
US | 16/136,168 | 19 Sep 2018 | US 2019/0002923 A1 | 03 Jan 2019 |
US | 16/136,175 | 19 Sep 2018 | US 2019/0010520 A1 | 10 Jan 2019 |
US | 16/201,836 | 27 Nov 2018 | US 2019/0093129 A1 | 28 Mar 2019 |
US | 16/201,848 | 27 Nov 2018 | US 2019/0106711 A1 | 11 Apr 2019 |
US | 16/201,853 | 27 Nov 2018 | US 2019/0106712 A1 | 11 Apr 2019 |
US | 16/201,855 | 27 Nov 2018 | US 2019/0106713 A1 | 11 Apr 2019 |
US | 16/201,862 | 27 Nov 2018 | US 2019/0106714 A1 | 11 Apr 2019 |
US | 16/201,865 | 27 Nov 2018 | US 2019/0106715 A1 | 11 Apr 2019 |
US | 16/276,343 | 14 Feb 2019 | ||
US | 16/276,348 | 14 Feb 2019 | ||
US | 16/276,352 | 14 Feb 2019 | ||
US | 16/276,356 | 14 Feb 2019 | ||
US | 16/276,361 | 14 Feb 2019 | ||
US | 16/276,365 | 14 Feb 2019 | ||
US | 16/276,368 | 14 Feb 2019 | ||
US | 16/276,374 | 14 Feb 2019 | ||
US | 16/277,090 | 15 Feb 2019 | ||
US | 16/380,758 | 10 Apr 2019 | ||
US | 16/380,781 | 10 Apr 2019 | ||
US | 16/382,093 | 11 Apr 2019 | ||
US | 16/382,096 | 11 Apr 2019 | ||
US | 16/382,097 | 11 Apr 2019 | ||
US | 16/382,100 | 11 Apr 2019 | ||
US | 16/383,412 | 12 Apr 2019 | ||
US | 16/383,422 | 12 Apr 2019 | ||
US | 16/383,433 | 12 Apr 2019 | ||
US | 16/383,443 | 12 Apr 2019 | ||
US | 16/385,360 | 16 Apr 2019 | ||
US | 16/385,383 | 16 Apr 2019 | ||
UZ | IAP20140559 | 15 Mar 2013 | ||
VN | 1-2014-04335 | 15 Mar 2013 | ||
ZA | 2017/00720 | 30 Jan 2017 |
Sigma-Aldrich CRISPR Use License Agreement
Abcam provides its modified cell lines that have been generated using CRISPR technology under a license agreement with Sigma-Aldrich Co. LLC. (“Sigma”) that contains certain limitations and obligations. By purchasing such modified cell lines, you, (the “Buyer”), hereby agree to use the modified cell lines for your own internal research only, and in accordance with the CRISPR Use License Agreement (“License Agreement”) set out below:
This Product and its use are the subject of one or more of the following patents and applications controlled by Sigma: Patent applications and issued patents that entered their respective National Stage from PCT International Pub. No. WO 2014/089290, including, but not limited to, the following, and substitutions, divisions, continuations, continuations-in-part, reissues, reexaminations, and extensions thereof: Australia Patent Nos. 2013355214; 2017204031; and 2018229489; Canada Patent No. 2,891,347; China Patent No. CN105142669; European Patent Nos. EP 3 138 910 B1, 3 138 911 B1, and EP 3 138 912 B1; Israel Patent No. IL238856; Singapore Patent No. 11201503824S; South Korea Patent No. 10- 1844123; and U.S. Patent Application Serial Nos. 15/188,911; 15/188,924; 15/188,927; 15/188,931; and 15/456,204 (the “Patent Rights”).
BEFORE OPENING OR USING THIS PRODUCT, PLEASE READ THE TERMS AND CONDITIONS SET FORTH IN THIS LICENSE AGREEMENT. YOUR USE OF THIS PRODUCT SHALL CONSTITUTE ACKNOWLEDGMENT AND ACCEPTANCE OF THESE TERMS AND CONDITIONS.
The purchase of this Product conveys to you, the Buyer, the NON-TRANSFERABLE right to use the purchased Product for Licensed Research Use (see definition below) subject to the conditions set out in this License Agreement. If you wish to use this Product for any purpose other than Licensed Research Use, you must first obtain an appropriate license (see information set out below).
This Product may not be used for any purpose other than Licensed Research Use. Your right to use this Product for Licensed Research Use is subject to the following conditions and restrictions:
1. Licensed Research Use means any use for research purposes, with the following exceptions:
i. Buyer may not sell or otherwise transfer the Product (including without limitation any material that contains the Product in whole or part) or any Related Material to any other third party (except that you may transfer the Product, including without limitation any material that contains the Product in whole or in part, or any Related Material to a bona fide collaborator or contract research person or entity), or use the Products or any Related Material to perform services for the benefit of any other person or entity;
ii. Buyer may use only the purchased amount of the Product and components of the Product, and shall use any Related Material, only for your internal research within the Field, and not for any Commercial Purposes;
iii. Buyer shall use the Product and any Related Material in compliance with all applicable laws and regulations, including without limitation applicable human health and animal welfare laws and regulations;
iv. Sigma shall provide no warranties of any kind to the Buyer (statutory or implied) concerning the Patent Rights, the Product or any Related Materials, including without limitation, as to product quality, condition, description, merchantability, fitness for a particular purpose, noninfringement of intellectual property rights or the absence of latent or other defects, and all such warranties are hereby expressly disclaimed;
v. Sigma shall expressly disclaim any warranty regarding results obtained through the use of the Product or Related Materials, including without limitation any claim of inaccurate, invalid or incomplete results;
vi. Sigma, and their directors, officers, employees and agents, shall have no liability to the Buyer, including, without limitation, for any loss of use or profits, business interruption or any consequential, incidental, special or other indirect damages of any kind, regardless of how caused and regardless of whether an action in contract, tort, strict product liability or otherwise;
vii. the Buyer shall indemnify, defend, and hold harmless Sigma and their current and former directors, officers, employees and agents, and their respective successors, heirs and assigns (the Indemnities) against any liability, damage, loss, or expense (including without limitation reasonable attorneys’ fees and expenses) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to the exercise of any rights granted to the Buyer hereunder or any breach of this License Agreement by such Buyer; and
viii. the Product and its use may be the subject of one or more issued patents and/or pending patent applications owned by Sigma and the purchase of the Product does not convey a license under any claims in the foregoing patents or patent applications directed to the Licensed Product or use, production or commercialization thereof.
For purposes of Section 1 above, the following definitions shallapply:
Commercial Purposes means (a) the practice, performance or provision of any method, process or service, or (b) the manufacture, sale, use, distribution, disposition or importing of any product, in each case (a) or (b) for consideration, e.g., a fee, or on any other commercial basis.
Field means use as a research tool for research purposes; provided, however, that notwithstanding the foregoing, the Field shall expressly exclude (a) any in vivo and ex vivo human or clinical use, including, without limitation, any administration into humans or any diagnostic or prognostic use, (b) the creation of transgenic rodent models and/or derivatives thereof (including, but not limited to, rodents’ cells and rodents’ organs) by for-profit entities, (c) any in vivo veterinary or livestock use, or non-research agricultural use, or (d) the manufacture, distribution, importation, exportation, transportation, sale, offer for sale, marketing, promotion or other exploitation or use of, or as, a testing service, therapeutic or diagnostic for humans or animals.
Related Materials means any progeny, modification or derivative of a Product.
2. Your right to use the Product will terminate immediately if you fail to comply with these terms and conditions. You shall, upon such termination of your rights, destroy all Product, Related Materials, and components thereof in your control, and notify Sigma of such in writing. For information on purchasing a license to this Product for purposes other than Licensed Research Use, contact your local Sigma sales representative, who will refer you to the proper licensing representative, or in the USA call 800-325-3010.
Sigma-Aldrich Patent Rights:
Patent applications and issued patents that entered their respective National Stage from PCT International Pub. No. WO 2014/089290
Limited Use Licenses for ioNEURONS/glut - Glutamatergic Neurons
This Product is provided by Bit Bio Ltd (Bit Bio) in partnership with Abcam Ltd (Abcam) under license from iPS Academia Japan, TET Systems GmbH, ERS Genomics Limited and Sigma-Aldrich Co. LLC.
Use of the Product is restricted to the terms contained within the individual Limited Use License Notices from each of the Licensors as set out below, and also by the general restriction that the User must only use the Product, Progeny, any Modifications of the Product and any Unmodified Derivatives of the Product in the Field.
The following Definitions apply to all Limited Use License Notices.
Field: Internal research use only. No Commercial Use is allowed.
Commercial Use: Any and all uses of the Product, Progeny, Modifications or Unmodified Derivatives thereof, by a party for monetary or other consideration and can include, but is not limited to use in:
(i) Manufacture of a Product;
(ii) Sale of a Product, Progeny, Modifications or Unmodified Derivatives thereof, whether or not such sale is limited for use in research;
(iii) Provision of a service to a third party;
(iv) Use in any diagnostic, preventative, or therapeutic application;
(v) Use in any veterinary, livestock or agricultural application; and
(vi) Use in later stage development of therapeutics, diagnostics, prophylactics (e.g., hit-to-lead, lead optimization).
Product: Cells which are differentiated from human iPS cells by Bit Bio Ltd., and which Bit Bio Ltd. sells, or are sold on behalf of Bit Bio Ltd. by a distributor
Progeny: Any unmodified descendant form of the Product
Modifications: Any modifications of the Product
Unmodified Derivatives: Any substances created by the User that constitute an unmodified functional subunit or product expressed by the Product
User: The person or entity who purchased the Product(s) from Abcam in partnership with Bit Bio.
iPS Academia Japan, Inc.
The Product is sold by Abcam in partnership with Bit Bio under license from iPS Academia Japan, Inc (iPS-AJ). The Product is covered by one or more claims of issued patents and pending patent applications, including: U.S. Patent Nos. 8,048,999, 8,058,065, 8,129,187 and 8,278,104 and foreign counterparts thereof, including their divisions, continuations, extensions, substitutions, and those claiming priority therefrom or those claiming the same priorities therein.
The use of this Product is strictly limited to User’s own internal research as described in the iPS-AJ User Restrictions Notice set out below:
TET Systems GmbH
This Product contains the Tetracycline controllable expression system (the "Tet Technology"). The Tet Technology IP portfolio is proprietary to TET Systems GmbH & Co. KG (''TET Systems") and comprises a series of patents including U.S. patents 8,383,364, 9,181,556, European Patents EP 1954811, 2352833 and corresponding patent claims outside these regions. The purchaser of the Product (i.e. the User) is granted an automatic license to use the Tet Technology in the Field and excludes the right to transfer or sell the Product, the Tet Technology or its component parts to third parties. Users whose research using the Product is sponsored by for-profit organizations, which shall receive ownership to any data or results stemming from the sponsored research, shall need a license agreement from TET Systems in order to use this Product.
All Users of the Product acknowledge that the Tet Technology is experimental in nature. TET Systems makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products.
Under the terms specified in the Limited Use License all Users of this Product that do not have a license from TET Systems will be restricted to the purchase of less than 10 units of Product per annum. If the User is purchasing more than 10 units of Product per annum, a TET license will be required from TET Systems GmbH & Co. KG - please contact Abcam.
ERS GENOMICS Limited
CRISPR Non-Exclusive License Agreement
Certain commercial entities and/or activities performed at commercial entities may require additional contract rights from ERS Genomics Limited which are not granted through the purchase of this product. For additional information please see www.ersgenomics.com.
The User (purchaser) receives a non-exclusive, non-transferable right to use the Product, Progeny, Modifications and Unmodified Derivatives for RESEARCH USE ONLY, which, subject to the exclusions below, includes use to discover and develop any product, including therapeutic products, which may then be sold to third parties, provided, however, that such products do not incorporate the Product, Progeny, Modifications, or Unmodified Derivatives.
For clarity, transfer of materials or provision of services by not for profit or academic core labs to their internal clients shall not constitute Commercial Use.
Except for the rights granted herein, any and all rights to the Product, Progeny, Modifications or Unmodified Derivatives thereof, shall remain in Bit Bio Ltd. No ownership rights are transferred.
The User shall have no right to assign the rights granted herein to third parties. The Product, Progeny, Modifications or Unmodified Derivatives thereof, must at all times remain in the possession of the User, except for a transfer to a scientific collaborator or to a service provider, to perform services, solely on behalf of the User.
ERS Genomics Limited is an intended third-party beneficiary under these Terms of Use.
Sigma-Aldrich Co. LLC
ZFN License Agreement
This Product and its use are the subject of one or more of the following patents controlled by Sangamo BioSciences, Inc.: U.S. Patent Nos. 6,534,261, 6,607,882, 6,746,838, 6,794,136, 6,824,978, 6,866,997,
6,933,113, 6,979,539, 7,013,219, 7,030,215, 7,220,719, 7,241,573, 7,241,574, 7,585,849, 7,595,376,
6,903,185, 6,479,626, US20030232410, US20090203140 and corresponding foreign patent applications and patents.
BEFORE OPENING OR USING THIS PRODUCT, PLEASE READ THE TERMS AND CONDITIONS SET FORTH IN THIS LICENSE AGREEMENT. YOUR USE OF THIS PRODUCT SHALL CONSTITUTE ACKNOWLEDGMENT AND ACCEPTANCE OF THESE TERMS AND CONDITIONS.
The purchase of this Product conveys to the User, the non-transferable right to use the purchased Product in the Field. If you wish to use this Product for any purpose other than Licensed Research Use, you must first obtain an appropriate license from Sigma-Aldrich Co. LLC